Tyra Biosciences, Inc. (TYRA) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. Tyra Biosciences is a clinical-stage biotechnology company developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology. The company operates as a single segment focused on targeted oncology and genetically defined conditions, with no product revenue to date.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(39.3) million | $(28.1) million |
| Net Loss Per Share (Basic/Diluted) | $(0.64) | $(0.47) |
| Operating Expenses | $42.0 million | $31.9 million |
| Cash, Cash Equivalents & Marketable Securities | $383.5 million | $256.0 million |
| Net Cash Used in Operating Activities | $(32.6) million | $(25.5) million |
| Accumulated Deficit | $(410.6) million | $(279.5) million |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $11.2 million (40%) compared to Q1 2025, driven primarily by higher research and development (R&D) and general and administrative (G&A) expenses.
- R&D Expense Growth: R&D expenses rose $8.5 million to $33.5 million. This was driven by a $4.5 million increase in external costs for dabogratinib clinical trials (SURF302, BEACH301, and start-up of SURF303) and a $3.8 million increase in personnel costs due to headcount growth.
- G&A Expense Growth: G&A expenses increased $1.6 million to $8.5 million, primarily due to higher compensation and stock-based compensation costs.
- Capital Raise: The company generated $147.9 million in net proceeds from an at-the-market (ATM) offering program during the quarter, significantly boosting liquidity.
- Investing Activities: Net cash used in investing activities was $120.2 million, primarily due to $162.2 million in purchases of marketable securities, offset by $42.1 million in maturities.
Outlook, Guidance, and Risks
- Liquidity Runway: Management believes current cash, cash equivalents, and marketable securities ($383.5 million) are sufficient to fund operations into the second half of 2028.
- Clinical Milestones:
- SURF302 (IR NMIBC): Initial three-month complete response data expected in August 2026.
- BEACH301 (Achondroplasia): Initial safety sentinel cohort results expected in Q4 2026.
- SURF303 (LG-UTUC): First patient dosed; initial results expected in 2027.
- Risks: The company has never generated revenue and expects to incur significant losses until regulatory approval is obtained. Future capital requirements depend on clinical trial outcomes, regulatory approvals, and the ability to raise additional funds. There are no material legal proceedings pending.
Key Investor Verification Points
- Cash Burn Rate: Verify the sustainability of the $32.6 million quarterly operating cash burn against the projected runway to late 2028.
- ATM Program Capacity: Confirm remaining capacity under the $150 million ATM agreement (approx. $2.1 million remaining after Q1 sales) and potential need for additional equity financing.
- Clinical Trial Enrollment: Monitor patient enrollment rates and safety data for the three Phase 2 dabogratinib trials (SURF302, SURF303, BEACH301) as these are critical value drivers.
- Stock-Based Compensation: Note the $7.8 million in stock-based compensation expense for the quarter and the $74.4 million in unrecognized future costs.